Startup brief
Grid Bottlenecks and Mega-Rounds Shape UK Tech
Infrastructure snarls test neocloud valuations as venture fundraising hits record highs across deep-tech, silicon, and defence.
Startup
OMass's £230m mega-round proves deep-tech UK drug discovery can still draw transatlantic capital when backed by proprietary biophysical screening platforms.
BackgroundOMass Therapeutics was founded on Oxford academic breakthroughs in native mass spectrometry that capture fragile protein target structures in their natural state. Rare endocrine conditions such as congenital adrenal hyperplasia often lack targeted small-molecule treatments, forcing reliance on blunt steroid management.
- Bain Capital Life Sciences, Forbion, and Novo Holdings co-led the financing with participation from the state-backed British Business Bank, underscoring strong institutional support.
- Proceeds will advance lead candidate OMS1620 into Phase 2 trials for congenital adrenal hyperplasia and Cushing's syndrome to replace lifelong hormone replacement therapies.
- The startup is also generating human clinical proof-of-concept data for an oral immunology drug targeting systemic lupus, broadening its commercial pipeline beyond endocrine disorders.
Startup
British VC firms are stockpiling dry powder at record rates, securing the UK's venture lead across European deep-tech and artificial intelligence.
BackgroundEuropean startup investment declined significantly after central banks raised interest rates in 2022 to combat post-pandemic inflation. British fund managers have recently rebuilt capital reserves by establishing specialized multi-billion-pound vehicles focused on artificial intelligence and advanced silicon.
- Data from HSBC Innovation Banking and Dealroom shows UK startup investment climbed to $6.1bn during the third quarter alone, defying broader European stagnation.
- Semiconductor startups captured $497 million in third-quarter capital, pushing domestic chip venture funding to a record $1.6bn this year and outperforming software investment.
- Major closings included London-based Index Ventures raising $3.5bn across three funds and Highland Europe securing €1.1bn, giving domestic managers unprecedented dry powder.
Startup
Gridlock in British electrical infrastructure has struck Nscale's balance sheet, leaving its $35bn listing shorn of its primary corporate customer.
BackgroundNscale emerged as Britain's fastest-growing neocloud provider by leasing high-end Nvidia graphics processors to major enterprise technology clients. The company assembled a high-profile board featuring Sir Nick Clegg and Sheryl Sandberg to prepare for a major Wall Street stock debut.
- Microsoft cancelled a 50MW capacity lease after National Grid indicated full transmission energisation would not occur until after 2030, halting local infrastructure development.
- The Loughton site had been scheduled to deploy 23,000 Nvidia Blackwell chips to anchor Britain's independent compute reserves, leaving national AI capacity targets in doubt.
- Nscale maintains operational facilities in Norway, but the collapse of its domestic flagship site undermines its valuation case ahead of public trading on Wall Street.
Startup
MintNeuro is modularising brain-computer interfaces into off-the-shelf silicon, bypassing prohibitive custom semiconductor costs for neurotech startups.
BackgroundDeveloping custom microchips for brain-computer interfaces typically requires tens of millions of pounds and years of semiconductor engineering. Standardised low-power neuro-chips allow biomedical research teams to test clinical neural stimulation therapies at a fraction of standard development budgets.
- Odyssey Ventures led the seed funding round alongside Imperial College London, Alumni Ventures, and specialist semiconductor venture funds to accelerate commercial chip manufacturing.
- MintNeuro has already manufactured working silicon and secured commercial supply partnerships with US-based Motif Neurotech and Britain's Amber Therapeutics for clinical testing.
- The modular chips support neural recording and targeted neurostimulation therapies designed to treat drug-resistant clinical depression without bulky external hardware.
Startup
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
